Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07096999 · ClinicalTrials.gov registry record
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
A clinical trial of Metastatic Castration-resistant Prostate Carcinoma, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 60
- Enrollment target
- 1
- Study location
NCT07096999 is a study of Metastatic Castration-resistant Prostate Carcinoma that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 60 participants, above the 51-participant average among 8 other Metastatic Castration-resistant Prostate Carcinoma trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07096999, a study of Metastatic Castration-resistant Prostate Carcinoma, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2031-01-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07096999
The ClinicalTrials.gov registry entry for NCT07096999 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 51-participant average among 8 other Metastatic Castration-resistant Prostate Carcinoma trials with a reported enrollment target (18% higher). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Castration-resistant Prostate Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT07096999 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07096999 about?
NCT07096999 is a clinical study titled "SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy". This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
What is the current status of trial NCT07096999?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-01-23. Estimated completion is 2031-01-23.
What conditions does trial NCT07096999 study?
This clinical trial studies the following conditions: Metastatic Castration-resistant Prostate Carcinoma.
What interventions are being tested in trial NCT07096999?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT07096999?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07096999 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-resistant Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
RECRUITING · Phase 4
-
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 1
-
Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
RECRUITING · Phase 1
-
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
RECRUITING · Phase 1
-
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
RECRUITING · Phase 2
-
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.